Dyne

Dyne Therapeutics

The company develops oligonucleotide therapeutics to treat patients with genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1.

Entrada Therapeutics

This biopharmaceutical company develops intracellular medicines for patients with neuromuscular and rare diseases using its proprietary endosomal escape vehicle delivery platform.

Audentes Therapeutics

The company develops gene therapy products to treat patients with serious and rare neuromuscular diseases.

NMD Pharma

This company develops small molecule therapies for patients suffering from severe neuromuscular disorders to restore skeletal muscle function.

ARTHEx Biotech

This clinical-stage biotechnology company develops RNA-based treatments for patients with rare neuromuscular genetic diseases, including myotonic dystrophy type 1.

Edgewise

This biopharmaceutical company develops oral small molecule therapies to treat patients with rare skeletal and cardiac muscle diseases.

Solid Biosciences

This life science company develops gene therapy candidates for patients living with rare neuromuscular and cardiac diseases.

4DMT

This company develops targeted gene therapy medicines for patients with severe genetic and retinal diseases.